JCVI: CLC bio Signs Strategic Collaborative Agreement with J. Craig Venter Institute
Section Banner
Collaborator Release 09-Oct-2008



CLC bio Signs Strategic Collaborative Agreement
with J. Craig Venter Institute

Cambridge, Massachusetts, USA — October 7, 2008 — CLC bio, a world leading full-service bioinformatics solution provider announced today an agreement with the J. Craig Venter Institute, a not-for profit genomic-focused research institute. The accord consists of a multi-year site license for the entire CLC bio bioinformatics suite of products. The goal is to implement CLC bio's enterprise solution as a scientific platform across all JCVI sites. This enterprise solution will provide different research projects at JCVI with a coherent integration layer and a standardized way of developing custom software and specialized algorithms.

According to Granger Sutton, Senior Director of Informatics, "JCVI will benefit from implementing this enterprise solution, as it is a full enterprise platform that integrates, supports, and enhances workflows across different technologies and geographical sites. The CLC bio software platform impressed our evaluators with its advanced features and intuitive, user-friendly interface."

"We're proud to announce this strategic partnership with JCVI, a leader in genomic research," says CLC bio's North America CEO Jan Lomholdt. "This site license agreement represents another stamp of approval of CLC bio's solution by a globally recognized institution in the scientific community. This partnership will lead to magnificent accomplishments in the scientific arena," Lomholdt adds.   

The enterprise solution CLC bio will be implementing at JCVI contains both server structure and support for all major database formats. This ensures a smart and efficient solution for sharing centralized bioinformatics data in a client/server architecture, where the server contains one or more databases and the clients are CLC bio's workbenches.

CLC Bio's solution is a technological gateway that efficiently accesses all data and analysis in a single platform. With CLC bio's enterprise solution all proprietary algorithms and solutions developed at JCVI can be accessed from the same bioinformatics platform, ensuring a streamlined workflow with minimal overhead and no tedious time-wasting procedures. CLC bio's developer kit will enable JCVI to build targeted plug-ins for their internal use, while allowing JCVI to interact based on the same platform with worldwide collaborators. 

About CLC bio



For further information, please contact:
Jan Lomholdt
CEO, CLC bio North America
Cell phone: +1 (609) 216 3248
E-mail: jlomholdt(AT)clcbio.com